These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26504374)

  • 1. Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with L-phenylglycine scaffold.
    Zhang Y; Li X; Hou J; Huang Y; Xu W
    Drug Des Devel Ther; 2015; 9():5553-67. PubMed ID: 26504374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors.
    Li J; Li X; Wang X; Hou J; Zang J; Gao S; Xu W; Zhang Y
    Chem Biol Drug Des; 2016 Oct; 88(4):574-84. PubMed ID: 27235003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
    Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
    Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
    Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
    Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.
    Yao Y; Liao C; Li Z; Wang Z; Sun Q; Liu C; Yang Y; Tu Z; Jiang S
    Eur J Med Chem; 2014 Oct; 86():639-52. PubMed ID: 25218912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
    Cheng C; Yun F; He J; Ullah S; Yuan Q
    Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.
    Zhou Y; Dun Y; Fu H; Wang L; Pan X; Yang X; Fang H
    Chem Biol Drug Des; 2017 Nov; 90(5):936-942. PubMed ID: 28489276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
    Duan W; Li J; Inks ES; Chou CJ; Jia Y; Chu X; Li X; Xu W; Zhang Y
    J Med Chem; 2015 May; 58(10):4325-38. PubMed ID: 25906087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
    Pidugu VR; Yarla NS; Pedada SR; Kalle AM; Satya AK
    Bioorg Med Chem; 2016 Nov; 24(21):5611-5617. PubMed ID: 27665180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
    Li Y; Wang Y; Xie N; Xu M; Qian P; Zhao Y; Li S
    Eur J Med Chem; 2015 Jul; 100():270-6. PubMed ID: 26140961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
    Tashima T; Murata H; Kodama H
    Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.
    Aboeldahab AMA; Beshr EAM; Shoman ME; Rabea SM; Aly OM
    Eur J Med Chem; 2018 Feb; 146():79-92. PubMed ID: 29396364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors.
    Zhou M; Ning C; Liu R; He Y; Yu N
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3200-3. PubMed ID: 23639537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
    Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
    J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
    Zhao Y; Yu D; Wu H; Liu H; Zhou H; Gu R; Zhang R; Zhang S; Wu G
    Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
    Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
    ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
    Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
    Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
    Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
    Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinolone-based HDAC inhibitors.
    Balasubramanian G; Kilambi N; Rathinasamy S; Rajendran P; Narayanan S; Rajagopal S
    J Enzyme Inhib Med Chem; 2014 Aug; 29(4):555-62. PubMed ID: 25019596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.